Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Top Cited Papers
- 1 March 2006
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (4), 548-556
- https://doi.org/10.1016/j.ejca.2005.11.014
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Disruption of the Rb-Raf-1 Interaction Inhibits Tumor Growth and AngiogenesisMolecular and Cellular Biology, 2004
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Final results of a phase I study of the Raf-1 kinase inhibitor bay 43-9006 in patients with advanced refractory solid tumoursEuropean Journal Of Cancer, 2002
- ZD1839: targeting the epidermal growth factor receptor in cancer therapyExpert Opinion on Investigational Drugs, 2002
- Ras family genes: An interesting link between cell cycle and cancerJournal of Cellular Physiology, 2002
- Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras ActivationJournal of Biological Chemistry, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- VEGF Stimulates MAPK through a Pathway That Is Unique for Receptor Tyrosine KinasesBiochemical and Biophysical Research Communications, 1999